BioVie Inc. (NASDAQ:BIVIW – Get Free Report) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 20,933 shares, a drop of 51.6% from the September 15th total of 43,287 shares. Based on an average daily trading volume, of 15,170 shares, the days-to-cover ratio is presently 1.4 days.
BioVie Price Performance
Shares of BioVie stock remained flat at $0.25 during trading on Thursday. 6,786 shares of the company traded hands, compared to its average volume of 55,311. The firm’s 50-day simple moving average is $0.29 and its 200-day simple moving average is $0.33. BioVie has a 12-month low of $0.13 and a 12-month high of $0.79.
BioVie Inc is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and liver-related diseases. The company’s research programs are intended to address conditions associated with neuroinflammation, insulin resistance, chronic liver disease and complications of cirrhosis.
BioVie’s lead neurodegenerative disease candidate is bezisterim, also known as NE3107, an orally administered investigational therapy designed to cross the blood-brain barrier and modulate inflammatory signaling.
See Also
- Five stocks we like better than BioVie
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
